Table 4.
Specific treatments for Covid-19 according to inhalers prescriptions.
| Covid-19 therapy | Patients treated with bronchodilator inhalers N = 124 | Patients not treated with bronchodilator inhalers N = 203 | OR (95% CI) |
|---|---|---|---|
| Hydroxychloroquine | 119/124 (95.9%) | 190/203 (93.6%) | 1.642 (0.571–4.723) |
| Lopinavir/ritonavir | 29/124 (23.4%) | 33/203 (16.3%) | 1.556 (0.891–2.719) |
| Costicosteroids IV | 17/124 (13.7%) | 11/203 (5.4%) | 2.747 (1.242–6.079) |
| Tocilizumab | 14/124 (11.3%) | 20/203 (9.9%) | 1.154 (0.560–2.377) |
| Remdesivir |
6/124 (4.8%) |
12/203 (5.9%) |
0.803 (0.293–2.195) |
| Antimicrobials | 118/124 (95.2%) | 185/203 (91.1%) | 1.823 (0.699–4.754) |
| Azitromicyn | 91/124 (73.4%) | 110/203 (54.2%) | 2.263 (1.399–3.661) |
| Ceftriaxone | 79/124 (63.7%) | 135/203 (66.5%) | 0.865 (0.543–1.378) |
| Levofloxacin | 8/124 (6.5%) | 31/203 (15.3%) | 0.379 (0.168–0.864) |
| Other | 16/124 (12.9%) | 33/203 (16.2%) | 0.811 (0.431–1.527) |